Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × INDUSTRY × CT103A chimeric antigen receptor × Clear all

Phase

Phase 1 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

pembrolizumab 213 Carboplatin 119 Nivolumab 109 Gemcitabine 107 Paclitaxel 105 Cisplatin 88 Bevacizumab 85 Cyclophosphamide 77 Dexamethasone 67 Injections 62 Docetaxel 62 Pemetrexed 59 Fluorouracil 55 Capecitabine 55 atezolizumab 54 Rituximab 53 Cetuximab 52 130-nm albumin-bound paclitaxel 52 Oxaliplatin 47 Leucovorin 44 Lenalidomide 41 Ipilimumab 40 venetoclax 37 Azacitidine 37 Prednisone 33 Albumin-Bound Paclitaxel 33 fludarabine 32 Trastuzumab 32 Fulvestrant 32 Irinotecan 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05066646 2021-11-23

FUMANBA-1

Nanjing IASO Biotechnology Co., Ltd.

Phase 1/2 Unknown

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡